Loading
IARC estimates 7,981 new cancer cases and 4,431 cancer deaths in North Macedonia in 2024; the commonest new cancers are breast, trachea, bronchus and lung and colorectum. This page is assembled automatically from OnCo's data: 5 trials with a site there, 1 institution and 1 person, and says what OnCo does not yet hold.
Built partly from other countries' data. IARC's method code for North Macedonia's incidence estimate is 3b: national mortality estimates applied to model-based mortality-to-incidence ratios (neighbouring country registry data). Read the figures as a regional estimate, not a count.
| Site | New cases | Rate | OnCo page |
|---|---|---|---|
| Breast | 1,222 | 74.0 | Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer, HER2-positive breast cancer |
| Trachea, bronchus and lung | 995 | 27.6 | Lung cancer (all types), Non-small-cell lung cancer, Small-cell lung cancer |
| Colorectum | 925 | 24.6 | Colorectal cancer |
| Prostate | 701 | 37.3 | Prostate cancer |
| Bladder | 407 | 10.9 | Bladder & urothelial cancer |
| Stomach | 342 | 9.1 | Gastric & gastro-oesophageal junction cancer |
| Corpus uteri | 291 | 16.4 | Endometrial cancer |
| Pancreas | 245 | 6.5 | Pancreatic ductal adenocarcinoma |
| Brain, central nervous system | 227 | 7.5 | Glioma & glioblastoma |
| Liver and intrahepatic bile ducts | 223 | 5.7 | Hepatocellular carcinoma |
| Site | Deaths | Rate | OnCo page |
|---|---|---|---|
| Trachea, bronchus and lung | 952 | 25.5 | Lung cancer (all types), Non-small-cell lung cancer, Small-cell lung cancer |
| Colorectum | 518 | 12.5 | Colorectal cancer |
| Breast | 429 | 20.9 | Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer, HER2-positive breast cancer |
| Stomach | 287 | 7.4 | Gastric & gastro-oesophageal junction cancer |
| Prostate | 243 | 12.2 | Prostate cancer |
| Pancreas | 234 | 6.0 | Pancreatic ductal adenocarcinoma |
| Liver and intrahepatic bile ducts | 214 | 5.3 | Hepatocellular carcinoma |
| Brain, central nervous system | 207 | 6.1 | Glioma & glioblastoma |
| Bladder | 149 | 3.4 | Bladder & urothelial cancer |
| Larynx | 98 | 2.5 |
| Trial | Lead sponsor | ||||
|---|---|---|---|---|---|
| Phase 2 | Active not recruiting | Genentech, Inc. | 179 | 2026-08-28 | |
ALINA NCT03456076 | Phase 3 | Active not recruiting | Hoffmann-La Roche | 114 | 2026-07-15 |
lidERA NCT04961996 | Phase 3 | Active not recruiting | Hoffmann-La Roche | 622 | 2026-06-17 |
IPATunity130 NCT03337724 | Phase 3 | Completed | Hoffmann-La Roche | 176 | 2024-03-12 |
CLEOPATRA NCT00567190 | Phase 3 | Completed | Genentech, Inc. | 322 | 2019-12-13 |
Trial records in OnCo whose ClinicalTrials.gov entry lists at least one site in North Macedonia, captured 2026-10-07 to 2026-10-07. Recruiting first, then the most recently updated. The status is the study's overall status; whether a site in North Macedonia is open is on the registry page, under Contacts and Locations.
People whose main affiliation in OnCo is an institution or company in North Macedonia.
OnCo records approvals for United States, European Union, United Kingdom, Japan, China, Australia and India. North Macedonia is not one of them, so no approval in OnCo speaks for it. See the approvals by region matrix for what is held.
North Macedonia is not among the 60 countries ranked in the country coverage queue (November 2026), which ranks countries without a page by cases, deaths, research output and population. Know a source? Suggest an edit.